The Omnitura leadership team is comprised of pioneers representing a diversity of industries. Omnitura’s board members have led innovation and change in their respective industry sector. Most of Omnitura’s board members have served for over a decade, demonstrating their long-term commitment to the vision and social impact of Omnitura. The Company’s board and management team are unified by a shared conviction regarding the need for multivalent immuno-oncology therapies capable of addressing the complexity and heterogeneity of cancer as well as the burden due to comorbid chronic diseases.

 

Management Team ::

 

JAMES DAO    |    Co-CEO & Co-Founder

James Dao is a successful serial high tech inventor and co-founder based in Silicon Valley with over 35 years of experience in managing, inventing, developing, and commercializing advanced technologies and innovative applications.

As founder and CEO of entrepreneurial companies, Mr. Dao is known for commercializing visionary business concepts and innovative products that have stimulated paradigm shifts in their industries. These companies (in instrumentation, semiconductors materials, design tools and manufacturing equipment, and mobile computing and cell phone software) reached public market capitalizations of US$2.7 billion and US$1.5 billion respectively.

Mr. Dao’s technical accomplishments include developing next generation scanning electron beam microscopes that overcame previous limitations and allowed cancer research to progress since the 1970s. He also participated in the design of a pioneering machine that used radiation to treat cancer (now Varian’s medical instrument division).

Mr. Dao and friends realized the need for molecular diagnostics combined with multivalent pharmaceuticals to fight cancer and other devastating chronic diseases. Mr. Dao co-founded Genyous Biomed International Inc. in 2000 to implement this vision of addressing cancer with a strategy based on systems biology that led to the creation of a drug development platform for non-toxic multivalent molecularly directed therapies. Omnitura Therapeutics Inc. is the second company to spin out from Genyous.

 

SIMON SUTCLIFFE, M.D.    |    Vice Chairman, Societal Impact & Chief Medical Officer

Simon Sutcliffe, M.D., has a broad medical career including research in microbiology and immunology, clinical research in oncology, and leadership in the management of cancer care institutions and organizations. He was a Professor of Radiology at the University of Toronto, and was the President and CEO of the Ontario Cancer Institute/Princess Margaret Hospital in Toronto, Canada. Dr. Sutcliffe has published extensively in the area of radiation and medical oncology as applied to the treatment of lymphoma, leukemia and endocrine malignancies, fertility and gonadal functions in cancer patients, and cellular immuno-deficiency and immuno-modulation in cancer. From 2000 to 2008 Dr. Sutcliffe served as President of the British Columbia Cancer Agency (BCCA) in Vancouver, B.C., Canada. The Agency’s mandate is to provide a population-based cancer control and care program for the public of British Columbia. BCCA’s patient care is deployed through four hospitals and over 60 outreach centres. BCCA’s Cancer Research and Genomic Science Centres have won over $75 million of competitive R&D grants from Canadian and U.S. National Cancer Institutes.

Dr. Sutcliffe is a recognized leader and has served in the Canadian National Cancer Control community for many years. In November 2006, he was appointed Vice Chairman - Canadian Partnership Against Cancer, with responsibility for implementing objectives of the Canadian Strategy for Cancer Control with a five-year budget of $250 million. In January 2009 Dr. Sutcliffe was appointed chairman of this organization. Dr. Sutcliffe also serves as the President of the International Cancer Control Congress and President of Two Worlds Cancer Collaboration (the Canadian Branch of the International Network for Cancer Treatment and Research). Through these programs, Dr. Sutcliffe is actively involved in cancer-related healthcare projects in India, Nepal, Brazil and Tanzania.

In January 2009, Dr. Sutcliffe became Chief Medical Officer of Omnitura. In this capacity he oversees the medical science, regulatory approval, clinical development strategies, and the exploration of unmet medical needs that are well-served by the Company’s systems approach to therapy. In 2011, Dr. Sutcliffe was also appointed Vice Chairman-Societal Impact of Omnitura. As Vice Chairman-Societal Impact, Dr. Sutcliffe provides inspiration for the Company to continuously strive to create innovative and safe pharmaceutical products and rational clinical protocols to deliver benefits to patients while reducing healthcare costs to society.

 

JEFFREY DAO    |    Co-CEO, President and Co-Founder

Jeffrey Dao has nearly 30 years of experience in the creation and management of emerging technology and new business development. Mr. Dao began his career as co-founder and director of application engineering at Communication Intelligence Corporation (CIC), a leading developer of pattern recognition technologies. Over a period of 10 years, Mr. Dao became CIC’s VP of marketing and sales and contributed to the company’s successful IPO on Nasdaq. Mr. Dao also served as Senior Director of Business Development for Oracle Corporation where he helped to build strategic alliances to support the company’s CRM and e-Business objectives. Mr. Dao also served as Vice President of Business Development at Nokia Inc., where he managed acquisitions and built strategic alliances to support the company’s Internet-communications objectives.

Mr. Dao is a co-founder of Genyous Biomed. He has served as President & COO of Genyous Biomed since 2005. In 2007 Mr. Dao was appointed President and COO of Omnitura. In 2009 he was appointed Co-CEO and President of Omnitura. In this capacity Mr. Dao oversees key aspects of the company’s operations including product pre-clinical & clinical development, regulatory affairs, organization development, strategic alliance formation, and product management.

 

DAVID WILSON, Ph.D.    |    Chief Operating Officer

David Wilson, Ph.D., is a senior executive with extensive domestic and international experience leading biotech/pharm corporate development, operations, product development, project and alliance management, regulatory affairs in startup and mid-size life science companies. Dr. Wilson has an excellent track record of bringing new pharmaceutical products through different phases of research, development and commercialization, including currently marketed products such as the immuno-oncology drugs Yervoy and Opdivo. He has demonstrated successes in five biotechnology companies that have directly resulted in increased valuation and subsequent acquisition or IPO resulting in over $4B in shareholder value. Dr. Wilson has had increasing executive leadership roles in MAST Immunosystems (now Hitachi Medical), Aviron (now Medimmune/Astra Zeneca), Medarex (now Bristol Myers Squibb), Molecular Profiling Institute (now CarisDx), Advanced Biologics (China), and now Omnitura. His strengths are strategic planning and resourceful, hands-on tactical management in focused product development from laboratory to launch, creation of operational infrastructure to support technology development, and leading multifunctional teams to optimize the value of the science. As Chief Operating Officer of Omnitura Therapeutics, Dr. Wilson provides executive leadership in the execution of the Company’s drug development programs and strategic objectives.

 

LARRY GOLDENBERG, M.D.    |    Chief Medical Officer, Urology

Larry Goldenberg, M.D., is Professor and Chairman of the Department of Urologic Sciences at UBC, Director of Clinical Research at the Prostate Centre at Vancouver General Hospital, and a Fellow of the Canadian Academy of Health sciences. He is a co-founder of the Canadian Urologic-Oncology Group, and past-president of both the Canadian Urological Association and the Western section of the American Urological Association (USA and Canada).  Through his vision and leadership, the Prostate Centre at Vancouver General Hospital has developed into one of the top prostate research, education and healthcare delivery programs in the world.

Dr. Goldenberg was a pioneer in the use of intermittent hormone withdrawal for the management of prostate cancer, which is now used worldwide as a treatment option for this disease. His book, Prostate Cancer - All You Need to Know to Take an Active Part in Your Treatment, is considered one of the best reference sources for men with prostate disease in North America.

 

STEPHEN LAM, M.D.    |    Chief Medical Officer, Pulmonology & Co-Founder

Stephen Lam, M.D., is a doctor of pulmonary medicine and is also Professor of Medicine at the University of British Columbia. Dr. Lam also serves as Chairman of the Lung Tumour Group at the BC Cancer Agency. He has served on the advisory committees at the U.S. Department of Health and the National Cancer Institute in functional imaging, biomarkers and chemoprevention committees. He was the past president of the International Photodynamic Association, Regent of the World Association of Bronchology, and Governor of the American College of Chest Physicians in British Columbia. He is the principal investigator of several U.S. NCI sponsored Phase I and Phase II clinical trials of chemopreventive agents that include both prescription drugs and natural products. He has published over 150 peer-reviewed articles, 11 patents and 27 book chapters. He is recognized as one of the world’s leading experts in early lung cancer detection and chemoprevention.

Dr. Lam is also internationally recognized for his 25 years of scientific research in early lung cancer detection and chemoprevention. He is the co-inventor of the autofluorescence bronchoscopic device for localization of pre-neoplastic lesions and early lung cancer. The technology has been adopted by major endoscope companies worldwide. In 1999, he was the recipient of the Friesen-Rygiel Award for Outstanding Canadian Academic Discovery. In 2002, he was awarded the Gustav Killian Medal by the World Association of Bronchology for his pioneering contributions to the field of early lung cancer diagnosis. In 2007, he became the first MDS-Rix endowed Director of Early Lung Cancer Detection and Translational Research at the BC Cancer Agency. In 2008, he received the Distinguished Achievement Award and the Martin M. Hoffman Award for research excellence from the University of British Columbia. In 2008, Dr. Lam and his colleagues discovered a novel blood biomarker for early detection and surveillance of lung cancer after treatment—this marker is part of the multi-center Terry Fox Research Institute Pan-Canadian Early Lung Cancer Detection Study testing a multi-modal model to identify smokers at highest risk of lung cancer for combined spiral CT scan and autofluorescence bronchoscopy. In 2009, the International Association for the Study of Lung Cancer (IASLC) recognized Dr. Lam with the Joseph W. Cullen Award for life-time scientific achievements in prevention research of thoracic malignancies.


NORMAN J MAITLAND, Ph.D.    |    Chief Scientist

Norman J Maitland, Ph.D., graduated with First Class Honours in Biochemistry from the University of Glasgow, and holds a PhD in Cancer Studies from the University of Birmingham. Part of his Postgraduate research was carried out as a Robertson Research Fellow in Cold Spring Harbor laboratory (NY, USA) where he pioneered the introduction of DNA into mammalian cells to correct genetic defects. After postdoctoral research in Genetics at the University of Edinburgh, he was appointed as the first UK Lecturer in Molecular Pathology at the University of Bristol in 1983, to apply basic molecular biology in the diagnosis and treatment of clinical problems, including childhood, cervical and oral cancers. He remained in Bristol until 1991, until his appointment to his current post as Yorkshire Cancer Research (YCR) Professor of Molecular Biology at the University of York, where he is also Director of the YCR Cancer Research Unit and holds a Chair in the Hull-York Medical School.

Dr. Maitland's current research is focused on studies of gene expression control in prostate, therapy for human prostate cancer, and the analysis of tissue stem cells from prostate in vivo and in vitro, which resulted in the isolation, characterization and translational exploitation of tumor initiating cells (or cancer stem cells) from human prostate cancers in 2005.

Dr. Maitland sits on the advisory boards of a number of cancer charities, and acts as a key opinion leader to the Pharmaceutical industry for prostate cancer. He is past chair of the British Prostate Group, The European Society for Urological Research and has coordinated a number of pan-European Teams in Prostate Cancer Research. In 2009, Dr. Maitland was awarded the Chopin Award by the EAU for excellence in translational research. As Omnitura’s chief scientist, Dr. Maitland provides guidance on the Company’s research direction and activity.

 

JERRY NORSKOG    |    Executive Vice President, Strategy & Business Development

Jerry Norskog has over forty years of experience in the pharmaceutical industry, holding numerous senior management positions for various divisions of Johnson & Johnson in North America and throughout Asia Pacific. His Asia experience includes serving as President of Xian-Janssen Pharmaceutical Ltd., a Johnson & Johnson joint venture with Chinese state-owned partners, which under his leadership became the top ranked Sino-foreign joint venture in China. Mr. Norskog also served as President of Johnson & Johnson China Development. Mr. Norskog’s most recent engagement was as President of McNeil Consumer Healthcare, the division of Johnson & Johnson that markets Tylenol. Mr. Norskog is founder and Chairman emeritus of the Chinese Foreign Pharmaceutical Investment Association.

Mr. Norskog provides valuable insight on the global pharmaceutical markets and guidance on the cultivation of joint ventures and manufacturing & distribution alliances. Mr. Norskog also serves as Omnitura’s Executive Vice President of Strategy & Business Development. Mr. Norskog also serves as President and COO of Vitala Therapeutics, a Genyous affiliate dedicated to the commercialization of pharmaceuticals for early intervention and supportive care of chronic diseases.

 

JACK TROIA    |    CFO

Jack Troia was a partner at Deloitte & Touche for fourteen years and in public accounting for over twenty-five years. Mr. Troia was a National Director of the Financial Services Practice and responsible for the financial services practices in the local offices of Deloitte & Touche in Washington, DC and Milwaukee, Wisconsin. He has significant experience in accounting and auditing for public and private companies, mergers and acquisitions, initial and secondary public offerings, financial management, and general business matters. Over the years he has worked with a significant number of businesses, in all aspects of financial management, business planning, accounting, and information systems.

After retiring from Deloitte & Touche, Mr. Troia assumed a temporary position at Georgetown University as an adjunct professor. For over five years Mr. Troia was involved with dynamic growing companies as both COO and CFO. He was responsible for all financial and operating aspects including accounting, treasury, human resources, management information systems, and operations. As CFO of Omnitura, Mr. Troia is a member of the finance committee. He also leads the Company’s financial planning, control, and related strategies.

 

JAMES LEVISON   |    Corporate Secretary and Treasurer

James Levison is a senior finance and operations executive with over forty years of experience. He is skilled in strategic and tactical financial affairs including P & L management, capital raising (public and private sector), negotiations, and treasury and cash management. Mr. Levison is highly experienced in contract management, banking relations, international operations, revenue recognition, taxation and financial reporting. Mr. Levison’s accounting and consulting career began at Ernst and Young in Silicon Valley before moving into start-up management and operational roles. Mr. Levison has previously served as Chief Financial Officer of Zephyr Photonics, Inc., Liquid Engines, Inc., and VP Finance of Think3, Inc. He holds an MBA from the Amos Tuck School of Business, Dartmouth College plus a BA from Colorado College and was a CPA in California. Mr. Levison, as the Secretary and Treasurer, is a member of the finance committee. He is responsible for all equity and compensation transactions, and the management of cash planning and investments. He will also assist the President to oversee stock market matters during and after IPO.

 

AUDIE CHANG    |    CPA, VP Administration & Controller

Audie Chang is a consultant and former financial executive with broad experience working with biotech and software companies. His expertise includes public audits, IPO/M&A, SEC reporting, ERP systems and Sarbanes-Oxley compliance. Previously, he served as CFO and/or controller with both private and public growth companies in the Silicon Valley for over 25 years.  Mr. Chang began his career with Deloitte Touche in New York City where he became licensed as a CPA. He holds an MBA from NYU Stern School of Business and a BA from Binghamton University. Mr. Chang is a Board member of the Financial Executive International and served on the Audit Committee of the City of Foster City for eight years. As VP Administration and Controller, Mr. Chang is a member of the finance committee and is responsible for the financial planning and control of all projects, contract administration and SEC regulatory compliance.

 

JOHN OSTREM    |    Ph.D., Sr. Vice President, Bioinformatics, Collaborative Research

John Ostrem, Ph.D., has more than 30 years experience inventing new technology and bringing products to market. In 1982, he co-founded Communication Intelligence Corporation, a company specializing in natural input and electronic signature solutions where he served for 15 years as CTO and Senior VP of Research and Engineering. In 2001 Dr. Ostrem co-founded China MobileSoft, a company that developed telecommunications software for the Chinese and International markets, and at various times served as Chairman, CEO, and CTO. Dr. Ostrem began his career as a scientist and researcher at SRI (the former Stanford Research Institute). Dr. Ostrem has many scientific publications, patents, and has received numerous grants and awards from the National Science Foundation and NIST. As Sr. VP, Bioinformatics, Collaborative Research, Dr. Ostrem provides leadership on the Company’s translational research as it relates to data analysis & mining.


Board of Directors ::

 

JAMES DAO    |    Chairman & Co-Founder

James Dao is a successful serial high tech inventor and co-founder based in Silicon Valley with over 35 years of experience in managing, inventing, developing, and commercializing advanced technologies and innovative applications.

As founder and CEO of entrepreneurial companies, Mr. Dao is known for commercializing visionary business concepts and innovative products that have stimulated paradigm shifts in their industries. These companies (in instrumentation, semiconductors materials, design tools and manufacturing equipment, and mobile computing and cell phone software) reached public market capitalizations of US$2.7 billion and US$1.5 billion respectively.

Mr. Dao’s technical accomplishments include developing next generation scanning electron beam microscopes that overcame previous limitations and allowed cancer research to progress since the 1970s. He also participated in the design of a pioneering machine that used radiation to treat cancer (now Varian’s medical instrument division).

Mr. Dao and friends realized the need for molecular diagnostics combined with multivalent pharmaceuticals to fight cancer and other devastating chronic diseases. Mr. Dao co-founded Genyous Biomed International Inc. in 2000 to implement this vision of addressing cancer with a strategy based on systems biology that led to the creation of a drug development platform for non-toxic multivalent molecularly directed therapies. Omnitura Therapeutics Inc. is the second company to spin out from Genyous.

 

SIMON SUTCLIFFE, M.D.    |    Vice Chairman, Societal Impact & Director

Simon Sutcliffe, M.D., has a broad medical career including research in microbiology and immunology, clinical research in oncology, and leadership in the management of cancer care institutions and organizations. He was a Professor of Radiology at the University of Toronto, and was the President and CEO of the Ontario Cancer Institute/Princess Margaret Hospital in Toronto, Canada. Dr. Sutcliffe has published extensively in the area of radiation and medical oncology as applied to the treatment of lymphoma, leukemia and endocrine malignancies, fertility and gonadal functions in cancer patients, and cellular immuno-deficiency and immuno-modulation in cancer. From 2000 to 2008 Dr. Sutcliffe served as President of the British Columbia Cancer Agency (BCCA) in Vancouver, B.C., Canada. The Agency’s mandate is to provide a population-based cancer control and care program for the public of British Columbia. BCCA’s patient care is deployed through four hospitals and over 60 outreach centres. BCCA’s Cancer Research and Genomic Science Centres have won over $75 million of competitive R&D grants from Canadian and U.S. National Cancer Institutes.

Dr. Sutcliffe is a recognized leader and has served in the Canadian National Cancer Control community for many years. In November 2006, he was appointed Vice Chairman - Canadian Partnership Against Cancer, with responsibility for implementing objectives of the Canadian Strategy for Cancer Control with a five-year budget of $250 million. In January 2009 Dr. Sutcliffe was appointed chairman of this organization. Dr. Sutcliffe also serves as the President of the International Cancer Control Congress and President of Two Worlds Cancer Collaboration (the Canadian Branch of the International Network for Cancer Treatment and Research). Through these programs, Dr. Sutcliffe is actively involved in cancer-related healthcare projects in India, Nepal, Brazil and Tanzania.

In January 2009, Dr. Sutcliffe became Chief Medical Officer of Omnitura. In this capacity he oversees the medical science, regulatory approval, clinical development strategies, and the exploration of unmet medical needs that are well-served by the Company’s systems approach to therapy. In 2011, Dr. Sutcliffe was also appointed Vice Chairman-Societal Impact of Omnitura. As Vice Chairman-Societal Impact, Dr. Sutcliffe provides inspiration for the Company to continuously strive to create innovative and safe pharmaceutical products and rational clinical protocols to deliver benefits to patients while reducing healthcare costs to society.

 

DAVID ALBERTS, M.D.    |    Director

David Alberts, M.D., recently retired as director of the Arizona Cancer Center at the University of Arizona and is a recognized leader in research in the prevention of cancer. He is a Regents Professor of Medicine, Pharmacology, Nutritional Sciences, Public Health, and BIO5 Institute, the University of Arizona, Tucson, Arizona. Dr. Alberts has been funded by the National Cancer Institute (NCI) yearly since 1971 for laboratory and clinical research related to the clinical pharmacology of cancer chemotherapy and chemopreventive agents, as well as the development of research strategies for the prevention of breast, cervix, colon, prostate and skin cancers.

Dr. Alberts has authored or co-authored more than 400 peer-reviewed publications, has served as editor and co-editor of four books and has served on several editorial boards. Dr. Alberts also serves as Omnitura’s Chief Clinical Science Officer and plays a leadership role in shaping Omnitura’s clinical development programs.

 

JEFFREY DAO    |    Director & Co-Founder

Jeffrey Dao has nearly 30 years of experience in the creation and management of emerging technology and new business development. Mr. Dao began his career as co-founder and director of application engineering at Communication Intelligence Corporation (CIC), a leading developer of pattern recognition technologies. Over a period of 10 years, Mr. Dao became CIC’s VP of marketing and sales and contributed to the company’s successful IPO on Nasdaq. Mr. Dao also served as Senior Director of Business Development for Oracle Corporation where he helped to build strategic alliances to support the company’s CRM and e-Business objectives. Mr. Dao also served as Vice President of Business Development at Nokia Inc., where he managed acquisitions and built strategic alliances to support the company’s Internet-communications objectives.

Mr. Dao is a co-founder of Genyous Biomed. He has served as President & COO of Genyous Biomed since 2005. In 2007 Mr. Dao was appointed President and COO of Omnitura. In 2009 he was appointed Co-CEO and President of Omnitura. In this capacity Mr. Dao oversees key aspects of the company’s operations including product pre-clinical & clinical development, regulatory affairs, organization development, strategic alliance formation, and product management.

 

THOMAS KALINSKE    |    Director

Thomas Kalinske has extensive experience serving as the top executive of numerous dynamic multi-billion dollar international businesses. Mr. Kalinske currently serves as Vice Chairman of the Board of Leapfrog Enterprises Inc. He has served as Leapfrog’s CEO and on its Board of Directors since September 1997 and Chairman of the Board of Directors from September 1997 to February 2004. Mr. Kalinske is also Chairman of Cambium Learning Group (NASDQ: ABCD), and education company that provides curriculum for k-12 students with special needs and learning difficulties, as well as turnaround services for public schools. Additionally, Mr. Kalinske is Executive Chairman of Global Education Learning, a company currently engaged in buying and building education companies in China that provide services and a learning path for young children 2-7 years old.

From 1996 to February 2004, Mr. Kalinske served as the President of Knowledge Universe LLC (now renamed Krest LLC), a private company focused on building leading companies in areas relating to education, technology and career management and the improvement of individual and corporate performance. From 1990 to 1996, he served as President and Chief Executive Officer of Sega of America. Prior to that, he was President and Chief Executive Officer of the Universal Matchbox Group from 1987 to 1990. Prior to that, Mr. Kalinske served as President and Co-Chief Executive Officer of Mattel, Inc.

Mr. Kalinske also served for 20 years on the Board of the Milken Family Foundation, which is dedicated to improving health, finding cures for prostate and breast cancers, and improving education. He also served on the RAND Advisory Board for Education and Health issues, and the National Education Association Foundation Board for 10 years. He has been recognized as Man of the Year by the Starlight Foundation, the Boy Scouts of America, and is one of 15 living Americans inducted in the US "Toy Industry Hall of Fame".

 

JERRY NORSKOG    |    Director

Jerry Norskog has over forty years of experience in the pharmaceutical industry, holding numerous senior management positions for various divisions of Johnson & Johnson in North America and throughout Asia Pacific. His Asia experience includes serving as President of Xian-Janssen Pharmaceutical Ltd., a Johnson & Johnson joint venture with Chinese state-owned partners, which under his leadership became the top ranked Sino-foreign joint venture in China. Mr. Norskog also served as President of Johnson & Johnson China Development. Mr. Norskog’s most recent engagement was as President of McNeil Consumer Healthcare, the division of Johnson & Johnson that markets Tylenol. Mr. Norskog is founder and Chairman emeritus of the Chinese Foreign Pharmaceutical Investment Association. As a member of the board of directors, Mr. Norskog provides valuable insight on the global pharmaceutical markets and guidance on the cultivation of joint ventures and manufacturing & distribution alliances. Mr. Norskog also serves as Omnitura’s Executive Vice President of Strategy & Business Development. Mr. Norskog also serves as President and COO of Vitala Therapeutics, a Genyous affiliate dedicated to the commercialization of pharmaceuticals for early intervention and supportive care of chronic diseases.

 

LEE TING    |    Director

Lee Ting currently serves as a Managing Partner of WR Hambrecht Ventures I and II, an affiliate of WR Hambrecht + Co, an investment bank based in San Francisco. He is an independent Board Member of the Lenovo Group, a leading global IT company based in US and China, and Neophotonics Inc., a global supplier of optical components and modules to the telecommunications industry based in San Jose, CA. Mr. Ting is a former Corporate Vice President of Hewlett Packard Co. (HP) where he worked for more than thirty years. His last position at HP was Corporate Vice President and Managing Director of Worldwide Geographic Operations. During a two-year absence from HP in the late eighties, Mr. Ting was a Senior Vice President of Hambrecht & Quist where he played a key role in the expansion of the firm's venture capital business into Asia.